News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
701,174 Results
Type
Article (40407)
Company Profile (248)
Press Release (660519)
Multimedia
Podcasts (58)
Webinars (12)
Section
Business (204604)
Career Advice (2067)
Deals (35510)
Drug Delivery (98)
Drug Development (81444)
Employer Resources (172)
FDA (16256)
Job Trends (14904)
News (346203)
Policy (32634)
Tag
Academia (2579)
Accelerated approval (5)
Adcomms (21)
Allergies (86)
Alliances (49650)
ALS (88)
Alzheimer's disease (1387)
Antibody-drug conjugate (ADC) (132)
Approvals (16257)
Artificial intelligence (256)
Autoimmune disease (21)
Automation (16)
Bankruptcy (363)
Best Places to Work (11663)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (175)
Bladder cancer (80)
Brain cancer (28)
Breast cancer (283)
Cancer (2288)
Cardiovascular disease (176)
Career advice (1728)
Career pathing (30)
CAR-T (151)
Cell therapy (425)
Cervical cancer (21)
Clinical research (66307)
Collaboration (840)
Company closure (1)
Compensation (533)
Complete response letters (19)
COVID-19 (2601)
CRISPR (42)
C-suite (242)
Cystic fibrosis (100)
Data (2209)
Decentralized trials (2)
Denatured (18)
Depression (43)
Diabetes (271)
Diagnostics (6382)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (100)
Drug shortages (26)
Duchenne muscular dystrophy (93)
Earnings (86675)
Editorial (37)
Employer branding (21)
Employer resources (146)
Events (112613)
Executive appointments (724)
FDA (17520)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (750)
Gene editing (106)
Generative AI (20)
Gene therapy (303)
GLP-1 (715)
Government (4441)
Grass and pollen (4)
Guidances (67)
Healthcare (18871)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (120)
Indications (29)
Infectious disease (2743)
Inflammatory bowel disease (137)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (330)
IPO (16523)
IRA (41)
Job creations (3649)
Job search strategy (1458)
Kidney cancer (10)
Labor market (38)
Layoffs (468)
Leadership (17)
Legal (7936)
Liver cancer (77)
Lung cancer (322)
Lymphoma (155)
Machine learning (7)
Management (58)
Manufacturing (307)
MASH (67)
Medical device (13407)
Medtech (13412)
Mergers & acquisitions (19534)
Metabolic disorders (691)
Multiple sclerosis (81)
NASH (17)
Neurodegenerative disease (90)
Neuropsychiatric disorders (28)
Neuroscience (1927)
NextGen: Class of 2025 (6540)
Non-profit (4495)
Now hiring (39)
Obesity (365)
Opinion (217)
Ovarian cancer (76)
Pain (87)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (236)
Patient recruitment (112)
Peanut (47)
People (57413)
Pharmaceutical (64)
Pharmacy benefit managers (18)
Phase I (20611)
Phase II (29173)
Phase III (21811)
Pipeline (1210)
Policy (141)
Postmarket research (2589)
Preclinical (8754)
Press Release (64)
Prostate cancer (107)
Psychedelics (32)
Radiopharmaceuticals (246)
Rare diseases (382)
Real estate (5922)
Recruiting (65)
Regulatory (22351)
Reports (46)
Research institute (2334)
Resumes & cover letters (356)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (70)
Series A (130)
Series B (84)
Service/supplier (11)
Sickle cell disease (53)
Special edition (15)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3587)
State (2)
Stomach cancer (14)
Supply chain (68)
Tariffs (40)
The Weekly (38)
Vaccines (696)
Venture capitalists (42)
Weight loss (239)
Women's health (35)
Worklife (18)
Date
Today (26)
Last 7 days (899)
Last 30 days (2533)
Last 365 days (32723)
2025 (10774)
2024 (35311)
2023 (40147)
2022 (51282)
2021 (55826)
2020 (54204)
2019 (46710)
2018 (35159)
2017 (32213)
2016 (31626)
2015 (37651)
2014 (31431)
2013 (26463)
2012 (28689)
2011 (29384)
2010 (27459)
Location
Africa (729)
Alabama (53)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (38030)
Australia (6216)
California (6140)
Canada (2018)
China (528)
Colorado (267)
Connecticut (274)
Delaware (148)
Europe (81837)
Florida (913)
Georgia (206)
Idaho (58)
Illinois (538)
India (26)
Indiana (308)
Iowa (11)
Japan (162)
Kansas (105)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (895)
Massachusetts (4574)
Michigan (220)
Minnesota (391)
Mississippi (2)
Missouri (81)
Montana (29)
Nebraska (25)
Nevada (63)
New Hampshire (64)
New Jersey (1728)
New Mexico (28)
New York (1747)
North Carolina (969)
North Dakota (8)
Northern California (2684)
Ohio (204)
Oklahoma (14)
Oregon (34)
Pennsylvania (1377)
Puerto Rico (12)
Rhode Island (33)
South America (1104)
South Carolina (23)
South Dakota (1)
Southern California (2304)
Tennessee (101)
Texas (909)
United States (23159)
Utah (180)
Virginia (146)
Washington D.C. (62)
Washington State (555)
West Virginia (3)
Wisconsin (54)
701,174 Results for "simulations plus inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results
April 4, 2025
·
15 min read
Press Releases
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
April 21, 2025
·
9 min read
Press Releases
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum
March 10, 2025
·
1 min read
Press Releases
Simulations Plus to Participate in Upcoming Healthcare Investor Conferences
February 4, 2025
·
3 min read
Press Releases
Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date
March 20, 2025
·
2 min read
Business
Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report third quarter fiscal 2024 financial results after the market close on Tuesday, July 2, 2024.
June 18, 2024
·
2 min read
Biotech Beach
Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that Shawn O’Connor, chief executive officer, will participate in Craig-Hallum’s 21st Annual Institutional Investor Conference on Wednesday, May 29, 2024, in Minneapolis, MN.
May 22, 2024
·
1 min read
Business
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024.
April 3, 2024
·
15 min read
Press Releases
Simulations Plus Supported Development of Every FDA-Approved Drug in 2024
January 13, 2025
·
3 min read
Deals
Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum
Simulations Plus, Inc. announced the acquisition of Pro-ficiency Holdings, Inc. and its subsidiaries, a leader in providing simulation-enabled performance and intelligence solutions for clinical and commercial drug development.
June 12, 2024
·
8 min read
1 of 70,118
Next
